{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:34:13Z","timestamp":1788449653350,"version":"build-2803163510"},"reference-count":26,"publisher":"FapUNIFESP (SciELO)","issue":"10","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"abstract":"<jats:p>Abstract: The U.S. Food and Drug Administration (FDA) has stated that the prescription of remdesivir should be cautious for patients with estimated glomerular filtration rate (eGFR) &lt; 30 and some studies reported risk of adverse renal events. The available information on the renal safety profile for remdesivir is limited, thus we analyzed the renal and urinary adverse reactions attributed to remdesivir reported in a large open pharmacovigilance database. We obtained reports of remdesivir and other drugs used to treat COVID-19 (tocilizumab, hydroxychloroquine, lopinavir\/ritonavir) registered by September 30 2020, from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). We analyzed the reporting odds ratios (RORs) for reports of adverse renal and urinary events for remdesivir and other drugs. We found 2,922 reports with remdesivir registered in FAERS for COVID-19. Among these, 493 renal and urinary adverse effects (16.9%) were reported. The most frequent events were acute kidney injury (338; 11.6%), renal impairment (86; 2.9%), and renal failure (53; 1.8%). Versus hydroxychloroquine, lopinavir\/ritonavir, or tocilizumab, the use of remdesivir was associated with an increased chance of reporting renal and urinary disorders regardless of gender and age of patients (2.53; 95%CI: 2.10-3.06). The ROR remained significant when we restricted the analysis to hydroxychloroquine (4.31; 95%CI: 3.25-5.71) or tocilizumab (3.92; 95%CI: 2.51-6.12). Our results reinforce this already reported signal, emphasizing that it could be extremely useful for health professionals who prescribe this new antiviral to treat COVID-19, mainly knowing its low efficacy.<\/jats:p>","DOI":"10.1590\/0102-311x00077721","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T12:07:19Z","timestamp":1636718839000},"source":"Crossref","is-referenced-by-count":20,"title":["Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database"],"prefix":"10.1590","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-2851","authenticated-orcid":false,"given":"Nayara Aparecida de Oliveira","family":"Silva","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-9078","authenticated-orcid":false,"given":"Ana Laura de Sene Am\u00e2ncio","family":"Zara","sequence":"additional","affiliation":[{"name":"Universidade Federal de Goi\u00e1s,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2013","authenticated-orcid":false,"given":"Albert","family":"Figueras","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona,  Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8613-7953","authenticated-orcid":false,"given":"Daniela Oliveira de","family":"Melo","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2021]]},"reference":[{"key":"ref1","series-title":"Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment"},{"key":"ref2","series-title":"First COVID-19 treatment recommended for EU authorisation"},{"key":"ref3","series-title":"Anvisa aprova registro da vacina da Fiocruz\/AstraZeneca e de medicamento contra o coronav\u00edrus"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Rochwerg B","year":"2020","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity Trial Results","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"ref6","article-title":"Cad Sa\u00fade","volume":"37","author":"Santos-Pinto CDB","year":"2021","journal-title":"P\u00fablica"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/jps.22109","article-title":"Review of the basic and clinical pharmacology of sulfobutylether-\u00df- cyclodextrin (SBECD)","volume":"99","author":"Luke DR","year":"2010","journal-title":"J Pharm Sci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jcph.1077","article-title":"Clinical pharmacokinetics of sulfobutylether-\u00df-cyclodextrin in patients with varying degrees of renal impairment","volume":"58","author":"Hoover RK","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1681\/ASN.2020040509","article-title":"AKI in hospitalized patients with and without COVID-19 a comparison study","volume":"31","author":"Fisher M","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"ref10","series-title":"Summary on compassionate use: Remdesivir Gilead"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2020050589","article-title":"Remdesivir in patients with acute or chronic kidney disease and COVID-19","volume":"31","author":"Adamsick ML","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ekir.2020.10.005","article-title":"Safety of remdesivir in patients with acute kidney injury or CKD","volume":"6","author":"Thakare S","year":"2021","journal-title":"Kidney Int Rep"},{"key":"ref13","article-title":"Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?","author":"Pettit NN","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13629","article-title":"Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients a retrospective cohort from a developing nation","volume":"23","author":"Meshram HS","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"110532","DOI":"10.1016\/j.biopha.2020.110532","article-title":"Safety profile of the antiviral drug remdesivir an update","volume":"130","author":"Fan Q","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein J","year":"2020","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19 a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang Y","year":"2020","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/cpt.2145","article-title":"Remdesivir and acute renal failure a potential safety signal from disproportionality analysis of the WHO safety database","volume":"109","author":"G\u00e9rard AO","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","article-title":"Acute kidney injury in patients hospitalized with COVID-19","volume":"98","author":"Hirsch JS","year":"2020","journal-title":"Kidney Int"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00134-020-06153-9","article-title":"Acute kidney injury in critically ill patients with COVID-19","volume":"46","author":"Gabarre P","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies principle, methods, bias and interpretation","volume":"74","author":"Faillie JL","year":"2019","journal-title":"Therapie"},{"key":"ref22","series-title":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October 2020"},{"key":"ref23","first-page":"340","article-title":"Big data and pharmacovigilance data mining for adverse drug events and interactions","volume":"43","author":"Ventola CL","year":"2018","journal-title":"P T"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Determinants of under-reporting of adverse drug reactions a systematic review","volume":"29","author":"Hazell L","year":"2006","journal-title":"Drug Saf"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration","volume":"23","author":"Duggirala HJ","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","article-title":"Postmarketing safety surveillance where does signal detection using electronic healthcare records fit into the big picture?","volume":"36","author":"Coloma PM","year":"2013","journal-title":"Drug Saf"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csp\/v37n10\/1678-4464-csp-37-10-e00077721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T12:07:39Z","timestamp":1636718859000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2021001005024&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"alternative-id":["S0102-311X2021001005024"],"URL":"https:\/\/doi.org\/10.1590\/0102-311x00077721","relation":{},"ISSN":["1678-4464","0102-311X"],"issn-type":[{"value":"1678-4464","type":"electronic"},{"value":"0102-311X","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"e00077721"}}